Dr. Reddys share price has zoomed 2% and is presently trading at Rs 6,201.8.
Meanwhile, the BSE HEALTHCARE index is at 36,809.0 (up 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are SUVEN PHARMACEUTICALS (up 6.2%) and MAX HEALTHCARE INSTITUTE (up 5.1%).
KIMS (down 1.9%) and POLY MEDICURE (down 1.5%) are among the top losers today.
Over the last one year, Dr. Reddys has moved up from Rs 5,042.3 to Rs 6,201.8, registering a gain of Rs 1,159.5 (up 23.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,266.1 to 36,809.0, registering a gain of 45.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Cadila Healthcare (up 90.1%), Glenmark Pharma (up 89.8%) and GSK Pharma (up 83.8%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 78,761.3 (up 0.1%).
The top gainers among the BSE Sensex today are Ultratech Cement (up 3.2%) and JSW Steel (up 1.6%). The most traded stocks in the BSE Sensex are Tata Steel and M&M.
In the meantime, NSE Nifty is at 23,889.5 (up 0.1%). Ultratech Cement and Grasim Industries are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 62,970.0 to 78,761.3, registering a gain of 15,791.3 points (up 25.1%).
Dr. Reddys net profit grew 37.1% YoY to Rs 13,063 million for the quarter ended March 2024, compared to a profit of Rs 9,525 million a year ago. Net sales rose 12.6% to Rs 71,138 million during the period as against Rs 63,152 million in January-March 2023.
For the year ended March 2023, Dr. Reddys reported 106.5% increase in net profit to Rs 45,073 million compared to net profit of Rs 21,825 million during FY22. Revenue of the company grew 14.5% to Rs 246,697 million during FY23.
The current Price to earnings ratio of Dr. Reddys, based on rolling 12 month earnings, stands at 18.6.
Equitymaster requests your view! Post a comment on "Dr. Reddys Gains 2%; BSE HEALTHCARE Index Up 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!